Assetmark Inc. Has $39,000 Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Assetmark Inc. decreased its position in AtriCure, Inc. (NASDAQ:ATRC) by 95.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,406 shares of the medical device company’s stock after selling 27,910 shares during the quarter. Assetmark Inc.’s holdings in AtriCure were worth $39,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Arcadia Investment Management Corp MI acquired a new position in AtriCure in the third quarter worth $28,000. Comerica Bank lifted its position in AtriCure by 70.5% during the 1st quarter. Comerica Bank now owns 2,522 shares of the medical device company’s stock worth $77,000 after buying an additional 1,043 shares in the last quarter. Quest Partners LLC increased its position in AtriCure by 38.3% in the 2nd quarter. Quest Partners LLC now owns 5,868 shares of the medical device company’s stock valued at $134,000 after acquiring an additional 1,626 shares in the last quarter. nVerses Capital LLC raised its stake in shares of AtriCure by 733.3% in the third quarter. nVerses Capital LLC now owns 5,000 shares of the medical device company’s stock worth $140,000 after acquiring an additional 4,400 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC grew its stake in shares of AtriCure by 32.1% during the second quarter. Mount Yale Investment Advisors LLC now owns 9,743 shares of the medical device company’s stock valued at $222,000 after purchasing an additional 2,368 shares during the last quarter. 99.11% of the stock is currently owned by institutional investors.

AtriCure Stock Down 0.9 %

Shares of AtriCure stock opened at $34.72 on Tuesday. AtriCure, Inc. has a 1 year low of $18.94 and a 1 year high of $43.00. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.62 and a quick ratio of 2.59. The company has a market capitalization of $1.69 billion, a P/E ratio of -41.83 and a beta of 1.41. The business has a 50-day moving average of $30.08 and a two-hundred day moving average of $25.43.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Tuesday, October 29th. The medical device company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.02. AtriCure had a negative net margin of 8.70% and a negative return on equity of 8.12%. The company had revenue of $115.91 million during the quarter, compared to analysts’ expectations of $112.23 million. During the same quarter in the prior year, the company earned ($0.20) earnings per share. The business’s quarterly revenue was up 17.9% compared to the same quarter last year. As a group, equities analysts predict that AtriCure, Inc. will post -0.72 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on ATRC. Needham & Company LLC lifted their target price on AtriCure from $34.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. BTIG Research reduced their target price on shares of AtriCure from $58.00 to $53.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. UBS Group boosted their price target on shares of AtriCure from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. lifted their target price on shares of AtriCure from $30.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. Finally, Canaccord Genuity Group increased their price target on AtriCure from $49.00 to $53.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.11.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.